Bigger Regulatory Challenges in Diagnostics Than in Therapeutics, Industry Expert Says
For makers of cancer therapies, the regulatory environment in Europe is likely to become more like that of the United States, and the FDA may extend its reach to areas such as next-generation sequencing. That’s what an industry expert told attendees gathered Sunday at a joint symposium of the American Society of Hematology (ASH) and…